Showing 1 - 10 of 401
Traditional value of medical innovation models estimate the benefits of a new treatment to individuals who fall sick ex-post. However, economic theory suggests medical innovation has additional benefits ex-ante - before susceptible individuals know whether or not they will fall sick. This paper...
Persistent link: https://www.econbiz.de/10012993523
Policymakers on both ends of the political spectrum have been looking for ways to reduce prescription drug prices. Democrats have also been working on expanding healthcare coverage, including different versions of Medicare for All. All these proposals have been framed as issues of access and...
Persistent link: https://www.econbiz.de/10012848087
Drug prices are uniquely susceptible to radical price reductions through generic competition. Patented pharmaceuticals may be priced at more than 30 times the marginal cost of production; the excess is the patent rent collected by the drug company while the patent and exclusive marketing periods...
Persistent link: https://www.econbiz.de/10014060277
Penicillin and other antibiotics were the original wonder drugs and laid the foundation of the modern pharmaceutical industry. Human health significantly improved with the introduction of antibiotics. By 1967, the US Surgeon General declared victory over infectious diseases in the US. But pride...
Persistent link: https://www.econbiz.de/10014060278
While neoclassical economic theory suggests that arbitrage will undermine global differential pricing of pharmaceuticals, the empirical results are more complex. Pharmaceutical regulation, IP laws, global trade agreements, and company policies support differential pricing despite the pressure of...
Persistent link: https://www.econbiz.de/10014070573
Scholars and policymakers across the ideological spectrum agree that the U.S. drug pricing system is deeply flawed. Most reform proposals focus on one symptom: high prices for existing drugs. But high prices aren’t all that ails the U.S. drug pricing system: Current law also provides weak...
Persistent link: https://www.econbiz.de/10014078244
The rise of blockbuster pharmaceutical acquisitions has prompted fears that unprecedented market concentration will weaken competition. Two of the most prominent concerns focus on the upstream and downstream ends of the pharmaceutical industry: (1) the concern that these mergers will concentrate...
Persistent link: https://www.econbiz.de/10011721586
In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private...
Persistent link: https://www.econbiz.de/10014060120
, obtained through price control legislation and legislation that eases the entry of generic products into the market, has caused …
Persistent link: https://www.econbiz.de/10004995401
the firms’ post-entry development. Nevertheless, few existing studies are dealing with questions of entrepreneurship in … the KIBS sector using micro firm data. This contribution gives an empirical analysis of the determinants of post-entry …-Classification: D21, J23, L80, O30 Keywords: Employment growth; Entrepreneurship; Entry; Innovation; Knowledge-intensive business …
Persistent link: https://www.econbiz.de/10011318984